Cable Hill Partners LLC Has $202,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Cable Hill Partners LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 42.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 892 shares of the medical instruments supplier’s stock after selling 649 shares during the quarter. Cable Hill Partners LLC’s holdings in Becton, Dickinson and Company were worth $202,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp lifted its stake in shares of Becton, Dickinson and Company by 0.8% in the third quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock worth $3,364,096,000 after buying an additional 106,616 shares during the last quarter. Geode Capital Management LLC raised its stake in Becton, Dickinson and Company by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock valued at $1,510,050,000 after purchasing an additional 111,101 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after purchasing an additional 460,440 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in Becton, Dickinson and Company by 31.0% during the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after purchasing an additional 673,568 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 1.4 %

Shares of BDX stock opened at $224.44 on Friday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The stock has a market cap of $64.44 billion, a price-to-earnings ratio of 37.28, a P/E/G ratio of 1.63 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The firm has a fifty day moving average of $233.13 and a 200-day moving average of $233.11.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 597 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $236.51, for a total transaction of $141,196.47. Following the sale, the executive vice president now owns 5,544 shares of the company’s stock, valued at $1,311,211.44. This represents a 9.72 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,544 shares of company stock valued at $2,370,309 in the last 90 days. 0.36% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Barclays upped their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and a consensus target price of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.